Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214779 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Phase 3 study of Ovarian Cancer, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 466
- Enrollment target
- 20
- Study locations
NCT07214779 is a Phase 3 study of Ovarian Cancer that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 466 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT07214779, a Phase 3 study of Ovarian Cancer, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 466 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Conditions Studied
Interventions
- DRUG INCB123667
- DRUG Investigator's choice of chemotherapy
Study Locations (20)
North Carolina
- Levine Cancer Center - Charlotte
- Novant Presbyterian Hospital - Charlotte
- Atrium Health Wake Forest Baptist - Winston-Salem
California
- City of Hope Medical Center - Duarte
- Valkyrie Clinical Trials - Los Angeles
Oregon
- Oncology Associates of Oregon, P.C. - Eugene
- Providence Cancer Institute Franz Clinic - Portland
Pennsylvania
- University of Pittsburgh Cancer Institute Cancer Services - Pittsburgh
- Wellspan Gynecologic Oncology - York
Georgia
- Georgia Cancer Center - Augusta
Illinois
- Northshore University Health System-Evanston Hospital - Evanston
Louisiana
- Women'S Cancer Care - Covington
Maine
- Maine Center For Cancer Medicine - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2029-05-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07214779
The ClinicalTrials.gov registry entry for NCT07214779 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (36% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which INCB123667 is the first listed.
NCT07214779 reports 20 study locations spanning 15 distinct geographic areas - top geographies include North Carolina, California, Oregon.
Frequently Asked Questions
What is clinical trial NCT07214779 about?
NCT07214779 is a clinical study titled "Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression". The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
What is the current status of trial NCT07214779?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 466 participants. The study started on 2025-12-09. Estimated completion is 2029-05-14.
What conditions does trial NCT07214779 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT07214779?
The interventions under investigation include: INCB123667 (DRUG), Investigator's choice of chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07214779?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214779 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Louisiana, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.